Global Long-acting Somatostatin Analogues (LA SSAs) Supply, Demand and Key Producers, 2024-2030

Page: 95

Published Date: 11 Oct 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Long-acting somatostatin analogues (LA SSAs) are synthetic derivatives of the natural hormone somatostatin, designed to mimic its effects while offering extended half-lives for prolonged therapeutic action. These medications primarily function to inhibit the secretion of growth hormone and other hormones, making them particularly effective in treating conditions such as acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders.

The global Long-acting Somatostatin Analogues (LA SSAs) market size is expected to reach $ million by 2030, rising at a market growth of %CAGR during the forecast period (2024-2030).

The market for long-acting somatostatin analogues (LA SSAs) is experiencing robust growth, driven by the rising prevalence of hormone-related disorders such as acromegaly and neuroendocrine tumors. As awareness of these conditions increases and diagnostic capabilities improve, more patients are being identified and treated with LA SSAs.

Recent advancements in formulation and delivery methods have also positively impacted the LA SSA market. The development of long-acting formulations allows for less frequent dosing, which enhances patient compliance and satisfaction. Additionally, ongoing research into new therapeutic applications of LA SSAs—such as their potential use in treating other endocrine disorders—expands their market appeal and encourages pharmaceutical companies to invest in further research and development.

Furthermore, the increasing focus on personalized medicine is shaping the market landscape for LA SSAs. Healthcare providers are increasingly tailoring treatments based on individual patient profiles, making the specific and targeted action of LA SSAs particularly valuable. As clinical guidelines continue to evolve and integrate LA SSAs into broader treatment protocols, the market is expected to grow steadily, with an expanding range of indications and improved therapeutic options for patients with hormone-related disorders.

This report studies the global Long-acting Somatostatin Analogues (LA SSAs) production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Long-acting Somatostatin Analogues (LA SSAs) and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Somatostatin Analogues (LA SSAs) that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Long-acting Somatostatin Analogues (LA SSAs) total production and demand, 2019-2030, (K Units)
Global Long-acting Somatostatin Analogues (LA SSAs) total production value, 2019-2030, (USD Million)
Global Long-acting Somatostatin Analogues (LA SSAs) production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units), (based on production site)
Global Long-acting Somatostatin Analogues (LA SSAs) consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Long-acting Somatostatin Analogues (LA SSAs) domestic production, consumption, key domestic manufacturers and share
Global Long-acting Somatostatin Analogues (LA SSAs) production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Long-acting Somatostatin Analogues (LA SSAs) production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Long-acting Somatostatin Analogues (LA SSAs) production by Application, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
This report profiles key players in the global Long-acting Somatostatin Analogues (LA SSAs) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Ipsen, Recordati Rare Diseases, Chiesi Farmaceutici S.p.A, Teva, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Long-acting Somatostatin Analogues (LA SSAs) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Long-acting Somatostatin Analogues (LA SSAs) Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Long-acting Somatostatin Analogues (LA SSAs) Market, Segmentation by Type:
    Injections
    Oral Capsules

Global Long-acting Somatostatin Analogues (LA SSAs) Market, Segmentation by Application:
    Neuroendocrine Tumors
    Acromegaly
    Other

Companies Profiled:
    Novartis
    Ipsen
    Recordati Rare Diseases
    Chiesi Farmaceutici S.p.A
    Teva

Key Questions Answered:
1. How big is the global Long-acting Somatostatin Analogues (LA SSAs) market?
2. What is the demand of the global Long-acting Somatostatin Analogues (LA SSAs) market?
3. What is the year over year growth of the global Long-acting Somatostatin Analogues (LA SSAs) market?
4. What is the production and production value of the global Long-acting Somatostatin Analogues (LA SSAs) market?
5. Who are the key producers in the global Long-acting Somatostatin Analogues (LA SSAs) market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Long-acting Somatostatin Analogues (LA SSAs) Introduction
    1.2 World Long-acting Somatostatin Analogues (LA SSAs) Supply & Forecast
        1.2.1 World Long-acting Somatostatin Analogues (LA SSAs) Production Value (2019 & 2023 & 2030)
        1.2.2 World Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030)
        1.2.3 World Long-acting Somatostatin Analogues (LA SSAs) Pricing Trends (2019-2030)
    1.3 World Long-acting Somatostatin Analogues (LA SSAs) Production by Region (Based on Production Site)
        1.3.1 World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Region (2019-2030)
        1.3.2 World Long-acting Somatostatin Analogues (LA SSAs) Production by Region (2019-2030)
        1.3.3 World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Region (2019-2030)
        1.3.4 North America Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030)
        1.3.5 Europe Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030)
        1.3.6 China Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030)
        1.3.7 Japan Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Long-acting Somatostatin Analogues (LA SSAs) Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Long-acting Somatostatin Analogues (LA SSAs) Major Market Trends

2 Demand Summary
    2.1 World Long-acting Somatostatin Analogues (LA SSAs) Demand (2019-2030)
    2.2 World Long-acting Somatostatin Analogues (LA SSAs) Consumption by Region
        2.2.1 World Long-acting Somatostatin Analogues (LA SSAs) Consumption by Region (2019-2024)
        2.2.2 World Long-acting Somatostatin Analogues (LA SSAs) Consumption Forecast by Region (2025-2030)
    2.3 United States Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030)
    2.4 China Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030)
    2.5 Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030)
    2.6 Japan Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030)
    2.7 South Korea Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030)
    2.8 ASEAN Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030)
    2.9 India Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030)

3 World Manufacturers Competitive Analysis
    3.1 World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Manufacturer (2019-2024)
    3.2 World Long-acting Somatostatin Analogues (LA SSAs) Production by Manufacturer (2019-2024)
    3.3 World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Manufacturer (2019-2024)
    3.4 Long-acting Somatostatin Analogues (LA SSAs) Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Long-acting Somatostatin Analogues (LA SSAs) Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Long-acting Somatostatin Analogues (LA SSAs) in 2023
        3.5.3 Global Concentration Ratios (CR8) for Long-acting Somatostatin Analogues (LA SSAs) in 2023
    3.6 Long-acting Somatostatin Analogues (LA SSAs) Market: Overall Company Footprint Analysis
        3.6.1 Long-acting Somatostatin Analogues (LA SSAs) Market: Region Footprint
        3.6.2 Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Type Footprint
        3.6.3 Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Value Comparison
        4.1.1 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Value Comparison (2019 & 2023 & 2030)
        4.1.2 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Comparison
        4.2.1 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Consumption Comparison
        4.3.1 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Consumption Comparison (2019 & 2023 & 2030)
        4.3.2 United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Consumption Market Share Comparison (2019 & 2023 & 2030)
    4.4 United States Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers and Market Share, 2019-2024
        4.4.1 United States Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value (2019-2024)
        4.4.3 United States Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2024)
    4.5 China Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers and Market Share
        4.5.1 China Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value (2019-2024)
        4.5.3 China Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2024)
    4.6 Rest of World Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers and Market Share, 2019-2024
        4.6.1 Rest of World Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value (2019-2024)
        4.6.3 Rest of World Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2024)

5 Market Analysis by Type
    5.1 World Long-acting Somatostatin Analogues (LA SSAs) Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Injections
        5.2.2 Oral Capsules
    5.3 Market Segment by Type
        5.3.1 World Long-acting Somatostatin Analogues (LA SSAs) Production by Type (2019-2030)
        5.3.2 World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Type (2019-2030)
        5.3.3 World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Long-acting Somatostatin Analogues (LA SSAs) Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Neuroendocrine Tumors
        6.2.2 Acromegaly
        6.2.3 Other
    6.3 Market Segment by Application
        6.3.1 World Long-acting Somatostatin Analogues (LA SSAs) Production by Application (2019-2030)
        6.3.2 World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Application (2019-2030)
        6.3.3 World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2019-2030)

7 Company Profiles
    7.1 Novartis
        7.1.1 Novartis Details
        7.1.2 Novartis Major Business
        7.1.3 Novartis Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        7.1.4 Novartis Long-acting Somatostatin Analogues (LA SSAs) Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.1.5 Novartis Recent Developments/Updates
        7.1.6 Novartis Competitive Strengths & Weaknesses
    7.2 Ipsen
        7.2.1 Ipsen Details
        7.2.2 Ipsen Major Business
        7.2.3 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        7.2.4 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.2.5 Ipsen Recent Developments/Updates
        7.2.6 Ipsen Competitive Strengths & Weaknesses
    7.3 Recordati Rare Diseases
        7.3.1 Recordati Rare Diseases Details
        7.3.2 Recordati Rare Diseases Major Business
        7.3.3 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        7.3.4 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.3.5 Recordati Rare Diseases Recent Developments/Updates
        7.3.6 Recordati Rare Diseases Competitive Strengths & Weaknesses
    7.4 Chiesi Farmaceutici S.p.A
        7.4.1 Chiesi Farmaceutici S.p.A Details
        7.4.2 Chiesi Farmaceutici S.p.A Major Business
        7.4.3 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        7.4.4 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.4.5 Chiesi Farmaceutici S.p.A Recent Developments/Updates
        7.4.6 Chiesi Farmaceutici S.p.A Competitive Strengths & Weaknesses
    7.5 Teva
        7.5.1 Teva Details
        7.5.2 Teva Major Business
        7.5.3 Teva Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        7.5.4 Teva Long-acting Somatostatin Analogues (LA SSAs) Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.5.5 Teva Recent Developments/Updates
        7.5.6 Teva Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Long-acting Somatostatin Analogues (LA SSAs) Industry Chain
    8.2 Long-acting Somatostatin Analogues (LA SSAs) Upstream Analysis
        8.2.1 Long-acting Somatostatin Analogues (LA SSAs) Core Raw Materials
        8.2.2 Main Manufacturers of Long-acting Somatostatin Analogues (LA SSAs) Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Long-acting Somatostatin Analogues (LA SSAs) Production Mode
    8.6 Long-acting Somatostatin Analogues (LA SSAs) Procurement Model
    8.7 Long-acting Somatostatin Analogues (LA SSAs) Industry Sales Model and Sales Channels
        8.7.1 Long-acting Somatostatin Analogues (LA SSAs) Sales Model
        8.7.2 Long-acting Somatostatin Analogues (LA SSAs) Typical Distributors

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Region (2019, 2023 and 2030) & (USD Million)
 Table 2. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Region (2019-2024) & (USD Million)
 Table 3. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Region (2025-2030) & (USD Million)
 Table 4. World Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share by Region (2019-2024)
 Table 5. World Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share by Region (2025-2030)
 Table 6. World Long-acting Somatostatin Analogues (LA SSAs) Production by Region (2019-2024) & (K Units)
 Table 7. World Long-acting Somatostatin Analogues (LA SSAs) Production by Region (2025-2030) & (K Units)
 Table 8. World Long-acting Somatostatin Analogues (LA SSAs) Production Market Share by Region (2019-2024)
 Table 9. World Long-acting Somatostatin Analogues (LA SSAs) Production Market Share by Region (2025-2030)
 Table 10. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Region (2019-2024) & (US$/Unit)
 Table 11. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Region (2025-2030) & (US$/Unit)
 Table 12. Long-acting Somatostatin Analogues (LA SSAs) Major Market Trends
 Table 13. World Long-acting Somatostatin Analogues (LA SSAs) Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
 Table 14. World Long-acting Somatostatin Analogues (LA SSAs) Consumption by Region (2019-2024) & (K Units)
 Table 15. World Long-acting Somatostatin Analogues (LA SSAs) Consumption Forecast by Region (2025-2030) & (K Units)
 Table 16. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Manufacturer (2019-2024) & (USD Million)
 Table 17. Production Value Market Share of Key Long-acting Somatostatin Analogues (LA SSAs) Producers in 2023
 Table 18. World Long-acting Somatostatin Analogues (LA SSAs) Production by Manufacturer (2019-2024) & (K Units)
 Table 19. Production Market Share of Key Long-acting Somatostatin Analogues (LA SSAs) Producers in 2023
 Table 20. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Manufacturer (2019-2024) & (US$/Unit)
 Table 21. Global Long-acting Somatostatin Analogues (LA SSAs) Company Evaluation Quadrant
 Table 22. World Long-acting Somatostatin Analogues (LA SSAs) Industry Rank of Major Manufacturers, Based on Production Value in 2023
 Table 23. Head Office and Long-acting Somatostatin Analogues (LA SSAs) Production Site of Key Manufacturer
 Table 24. Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Type Footprint
 Table 25. Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Application Footprint
 Table 26. Long-acting Somatostatin Analogues (LA SSAs) Competitive Factors
 Table 27. Long-acting Somatostatin Analogues (LA SSAs) New Entrant and Capacity Expansion Plans
 Table 28. Long-acting Somatostatin Analogues (LA SSAs) Mergers & Acquisitions Activity
 Table 29. United States VS China Long-acting Somatostatin Analogues (LA SSAs) Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 30. United States VS China Long-acting Somatostatin Analogues (LA SSAs) Production Comparison, (2019 & 2023 & 2030) & (K Units)
 Table 31. United States VS China Long-acting Somatostatin Analogues (LA SSAs) Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
 Table 32. United States Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Headquarters and Production Site (States, Country)
 Table 33. United States Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value, (2019-2024) & (USD Million)
 Table 34. United States Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share (2019-2024)
 Table 35. United States Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2024) & (K Units)
 Table 36. United States Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Market Share (2019-2024)
 Table 37. China Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Headquarters and Production Site (Province, Country)
 Table 38. China Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value, (2019-2024) & (USD Million)
 Table 39. China Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share (2019-2024)
 Table 40. China Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production, (2019-2024) & (K Units)
 Table 41. China Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Market Share (2019-2024)
 Table 42. Rest of World Based Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Headquarters and Production Site (State, Country)
 Table 43. Rest of World Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value, (2019-2024) & (USD Million)
 Table 44. Rest of World Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share (2019-2024)
 Table 45. Rest of World Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production, (2019-2024) & (K Units)
 Table 46. Rest of World Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Market Share (2019-2024)
 Table 47. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 48. World Long-acting Somatostatin Analogues (LA SSAs) Production by Type (2019-2024) & (K Units)
 Table 49. World Long-acting Somatostatin Analogues (LA SSAs) Production by Type (2025-2030) & (K Units)
 Table 50. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Type (2019-2024) & (USD Million)
 Table 51. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Type (2025-2030) & (USD Million)
 Table 52. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2019-2024) & (US$/Unit)
 Table 53. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2025-2030) & (US$/Unit)
 Table 54. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 55. World Long-acting Somatostatin Analogues (LA SSAs) Production by Application (2019-2024) & (K Units)
 Table 56. World Long-acting Somatostatin Analogues (LA SSAs) Production by Application (2025-2030) & (K Units)
 Table 57. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Application (2019-2024) & (USD Million)
 Table 58. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Application (2025-2030) & (USD Million)
 Table 59. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2019-2024) & (US$/Unit)
 Table 60. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2025-2030) & (US$/Unit)
 Table 61. Novartis Basic Information, Manufacturing Base and Competitors
 Table 62. Novartis Major Business
 Table 63. Novartis Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 64. Novartis Long-acting Somatostatin Analogues (LA SSAs) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 65. Novartis Recent Developments/Updates
 Table 66. Novartis Competitive Strengths & Weaknesses
 Table 67. Ipsen Basic Information, Manufacturing Base and Competitors
 Table 68. Ipsen Major Business
 Table 69. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 70. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 71. Ipsen Recent Developments/Updates
 Table 72. Ipsen Competitive Strengths & Weaknesses
 Table 73. Recordati Rare Diseases Basic Information, Manufacturing Base and Competitors
 Table 74. Recordati Rare Diseases Major Business
 Table 75. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 76. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 77. Recordati Rare Diseases Recent Developments/Updates
 Table 78. Recordati Rare Diseases Competitive Strengths & Weaknesses
 Table 79. Chiesi Farmaceutici S.p.A Basic Information, Manufacturing Base and Competitors
 Table 80. Chiesi Farmaceutici S.p.A Major Business
 Table 81. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 82. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 83. Chiesi Farmaceutici S.p.A Recent Developments/Updates
 Table 84. Chiesi Farmaceutici S.p.A Competitive Strengths & Weaknesses
 Table 85. Teva Basic Information, Manufacturing Base and Competitors
 Table 86. Teva Major Business
 Table 87. Teva Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 88. Teva Long-acting Somatostatin Analogues (LA SSAs) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 89. Teva Recent Developments/Updates
 Table 90. Teva Competitive Strengths & Weaknesses
 Table 91. Global Key Players of Long-acting Somatostatin Analogues (LA SSAs) Upstream (Raw Materials)
 Table 92. Global Long-acting Somatostatin Analogues (LA SSAs) Typical Customers
 Table 93. Long-acting Somatostatin Analogues (LA SSAs) Typical Distributors


List of Figures
 Figure 1. Long-acting Somatostatin Analogues (LA SSAs) Picture
 Figure 2. World Long-acting Somatostatin Analogues (LA SSAs) Production Value: 2019 & 2023 & 2030, (USD Million)
 Figure 3. World Long-acting Somatostatin Analogues (LA SSAs) Production Value and Forecast (2019-2030) & (USD Million)
 Figure 4. World Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030) & (K Units)
 Figure 5. World Long-acting Somatostatin Analogues (LA SSAs) Average Price (2019-2030) & (US$/Unit)
 Figure 6. World Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share by Region (2019-2030)
 Figure 7. World Long-acting Somatostatin Analogues (LA SSAs) Production Market Share by Region (2019-2030)
 Figure 8. North America Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030) & (K Units)
 Figure 9. Europe Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030) & (K Units)
 Figure 10. China Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030) & (K Units)
 Figure 11. Japan Long-acting Somatostatin Analogues (LA SSAs) Production (2019-2030) & (K Units)
 Figure 12. Long-acting Somatostatin Analogues (LA SSAs) Market Drivers
 Figure 13. Factors Affecting Demand
 Figure 14. World Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 15. World Long-acting Somatostatin Analogues (LA SSAs) Consumption Market Share by Region (2019-2030)
 Figure 16. United States Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 17. China Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 18. Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 19. Japan Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 20. South Korea Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 21. ASEAN Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 22. India Long-acting Somatostatin Analogues (LA SSAs) Consumption (2019-2030) & (K Units)
 Figure 23. Producer Shipments of Long-acting Somatostatin Analogues (LA SSAs) by Manufacturer Revenue ($MM) and Market Share (%): 2023
 Figure 24. Global Four-firm Concentration Ratios (CR4) for Long-acting Somatostatin Analogues (LA SSAs) Markets in 2023
 Figure 25. Global Four-firm Concentration Ratios (CR8) for Long-acting Somatostatin Analogues (LA SSAs) Markets in 2023
 Figure 26. United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share Comparison (2019 & 2023 & 2030)
 Figure 27. United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Production Market Share Comparison (2019 & 2023 & 2030)
 Figure 28. United States VS China: Long-acting Somatostatin Analogues (LA SSAs) Consumption Market Share Comparison (2019 & 2023 & 2030)
 Figure 29. United States Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Market Share 2023
 Figure 30. China Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Market Share 2023
 Figure 31. Rest of World Based Manufacturers Long-acting Somatostatin Analogues (LA SSAs) Production Market Share 2023
 Figure 32. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Type, (USD Million), 2019 & 2023 & 2030
 Figure 33. World Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share by Type in 2023
 Figure 34. Injections
 Figure 35. Oral Capsules
 Figure 36. World Long-acting Somatostatin Analogues (LA SSAs) Production Market Share by Type (2019-2030)
 Figure 37. World Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share by Type (2019-2030)
 Figure 38. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2019-2030) & (US$/Unit)
 Figure 39. World Long-acting Somatostatin Analogues (LA SSAs) Production Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 40. World Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share by Application in 2023
 Figure 41. Neuroendocrine Tumors
 Figure 42. Acromegaly
 Figure 43. Other
 Figure 44. World Long-acting Somatostatin Analogues (LA SSAs) Production Market Share by Application (2019-2030)
 Figure 45. World Long-acting Somatostatin Analogues (LA SSAs) Production Value Market Share by Application (2019-2030)
 Figure 46. World Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2019-2030) & (US$/Unit)
 Figure 47. Long-acting Somatostatin Analogues (LA SSAs) Industry Chain
 Figure 48. Long-acting Somatostatin Analogues (LA SSAs) Procurement Model
 Figure 49. Long-acting Somatostatin Analogues (LA SSAs) Sales Model
 Figure 50. Long-acting Somatostatin Analogues (LA SSAs) Sales Channels, Direct Sales, and Distribution
 Figure 51. Methodology
 Figure 52. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Novartis
Ipsen
Recordati Rare Diseases
Chiesi Farmaceutici S.p.A
Teva

Related Reports

Global Long-acting Somatostatin Analogues (LA SSAs) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Long-acting Somatostatin Analogues (LA SSAs) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 11 Oct 2024

date Pharma & Healthcare

Long-acting somatostatin analogues (LA SSAs) are synthetic derivatives of the natural hormone somatostatin, designed to mimic its effects while offering extended half-lives for prolonged therapeutic action. These medications primarily function to inhibit the secretion of growth hormone and other hormones, making them particularly effective in treating conditions such as acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders.

Product Tags

Long-acting Somatostatin Analogues (LA SSAs)

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>